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Abstract
Background: Administration of abciximab during primary percutaneous coronary intervention is
an effective adjunctive therapy in the treatment of patients with ST-segment elevation myocardial
infarction. Recent small-scaled studies have suggested that intracoronary administration of
abciximab during primary percutaneous coronary intervention is superior to conventional
intravenous administration. This study has been designed to investigate whether intracoronary
bolus administration of abciximab is more effective than intravenous bolus administration in
improving myocardial perfusion in patients with ST-segment elevation myocardial infarction
undergoing primary percutaneous coronary intervention with thrombus aspiration.
Methods/Design:  The Comparison of IntraCoronary versus intravenous abciximab
administration during Emergency Reperfusion Of ST-segment elevation myocardial infarction
(CICERO) trial is a single-center, prospective, randomized open-label trial with blinded evaluation
of endpoints. A total of 530 patients with STEMI undergoing primary percutaneous coronary
intervention are randomly assigned to either an intracoronary or intravenous bolus of weight-
adjusted abciximab. The primary end point is the incidence of >70% ST-segment elevation
resolution. Secondary end points consist of post-procedural residual ST-segment deviation,
myocardial blush grade, distal embolization, enzymatic infarct size, in-hospital bleeding, and clinical
outcome at 30 days and 1 year.
Discussion: The CICERO trial is the first clinical trial to date to verify the effect of intracoronary
versus intravenous administration of abciximab on myocardial perfusion in patients with ST-
segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
with thrombus aspiration.
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Background
ST-segment elevation myocardial infarction (STEMI) is
generally caused by rupture or erosion of atherosclerotic
plaque and subsequent platelet aggregation and thrombo-
sis, resulting in acute occlusion of a coronary artery [1,2].
The preferred treatment strategy consists of prompt reper-
fusion therapy by means of primary percutaneous coro-
nary intervention (PCI) [3-5]. However, despite optimal
reperfusion of the infarct-related coronary artery,
impaired myocardial perfusion is still present in a signifi-
cant proportion of patients following successful PCI,
which is associated with larger infarct size and increased
long-term cardiac mortality [6,7].
One of the major causes of impaired myocardial reper-
fusion is embolization of atherothrombotic material
including platelet aggregates into the distal microcircula-
tion [8]. In recent years, the implementation of adjunctive
mechanical and pharmacological therapies during pri-
mary PCI, including manual thrombus aspiration and
glycoprotein (GP) IIb/IIIa inhibitors, has significantly
reduced the occurrence of distal embolization and
improved clinical outcome in STEMI patients [9-15]. Sev-
eral trials and meta-analyses have demonstrated that man-
ual thrombus aspiration improved myocardial
reperfusion in patients presenting with STEMI and was
associated with improved survival compared to conven-
tional PCI at clinical follow-up up to 1 year [11,12,16-20].
However, a major limitation of thrombus aspiration is its
inability to prevent microvascular obstruction that has
occurred prior to PCI or that has been induced by primary
PCI including thrombus aspiration itself. Adjunctive
pharmacological therapies are therefore needed to target
these sources of microvascular obstruction.
Anti-platelet therapy is an important cornerstone of mod-
ern STEMI management. During PCI, the use of GP IIb/
IIIa inhibitors improves microvascular reperfusion
[13,14]. In large randomized trials, intravenous (IV)
administration of the GPIIb/IIIa inhibitor abciximab dur-
ing PCI was associated with a significant reduction in
short- and long-term mortality and reinfarction rates in
patients with STEMI [9,10,15]. An alternative approach
with the use of bivalirudin instead of the combination of
unfractionated heparin and a GPIIb/IIIa inhibitor has
been advocated and investigated [21]. Although this may
result in a lower rate of bleeding complications, a major
drawback seems to be the higher incidence of stent throm-
bosis.
Abciximab is the Fab fragment of the chimeric mono-
clonal antibody 7E3, which acts as a potent platelet aggre-
gation inhibitor mainly by binding to the GP IIb/IIIa
receptor on the surface of activated human platelets.
Hereby, abciximab inhibits the final common pathway
for platelet aggregation by preventing the binding of
fibrinogen and von Willebrand factor to activated plate-
lets [22]. A receptor occupancy study reported that the
absolute number of free GP IIb/IIIa receptors was
decreased in patients with successful restoration of myo-
cardial perfusion who were treated with GP IIb/IIIa inhib-
itors [23]. Experimental studies have reported additional
dose-dependent anti-platelet and anti-thrombotic effects
of abciximab, which is not only able to prevent thrombus
formation, but also to facilitate the dispersal of newly
formed platelet aggregates by displacement of platelet
bound fibrinogen with higher local drug concentration,
and to inhibit platelet-induced thrombin generation
[22,24,25]. In contrast to other GP IIb/IIIa inhibitors,
abciximab has also distinct non-GP IIb/IIIa-related prop-
erties that may reduce inflammatory pathways and reper-
fusion injury [26]. These dose-dependent anti-platelet,
anti-thrombotic and anti-inflammatory features of abcix-
imab suggest that a higher local platelet inhibitor concen-
tration may translate into further clinical improvements.
Higher local concentrations can be obtained by the direct
administration of abciximab into the infarct-related
artery.
Intracoronary (IC) administration of abciximab has been
investigated in several case reports and clinical studies
[27-35] (Table 1). A retrospective study suggested a signif-
icant clinical benefit of IC administration, showing a 50%
reduction of major adverse cardiac events (MACE) in
patients with acute coronary syndromes treated with IC
abciximab compared to IV abciximab [34]. A small pro-
spective randomized trial showed a greater degree of myo-
cardial salvage, better recovery of left ventricular function,
and improved myocardial perfusion in patients with
STEMI treated with IC abciximab [27]. Thiele et al [33]
reported a reduced infarct size and extent of microvascular
obstruction, and improved perfusion in patients treated
with an IC bolus of abciximab. In addition, there was a
trend towards a clinically relevant reduction in the inci-
dence of MACE in patients treated with IC abciximab
(5.2% vs. 15.6%, p = 0.06).
Given the limited number of patients included in these
trials, a larger randomized clinical trial is required to ver-
ify the effect of IC abciximab administration in STEMI
patients undergoing primary PCI. Furthermore, there is at
the present time no information with regard to the com-
bined strategy of thrombus aspiration and IC use of abcix-
imab. Therefore, we intend to determine the effect of IC
bolus administration of abciximab on post-procedural
myocardial perfusion compared to IV bolus administra-
tion in STEMI patients undergoing primary PCI with
thrombus aspiration.Trials 2009, 10:90 http://www.trialsjournal.com/content/10/1/90
Page 3 of 7
(page number not for citation purposes)
Methods/Design
The CICERO trial is a single-center, prospective, rand-
omized trial with blinded evaluation of endpoints (Figure
1). A total of 530 patients with STEMI undergoing primary
PCI are randomly assigned to either an IC or IV bolus of
weight-adjusted abciximab (0.25 mg/kg body weight,
ReoPro 2 mg/ml, Centocor B.V., Leiden, the Netherlands).
Randomization is performed by means of sealed enve-
lopes at the catheterization laboratory when a decision to
perform PCI is taken. The study takes place at a high-vol-
ume university hospital center providing 24-hours emer-
gency cardiac care with 7 referral hospitals in a region with
750,000 inhabitants. The study was approved by the insti-
tutional committee on human research of the University
Medical Center of Groningen and is in compliance with
the declaration of Helsinki. The protocol of this trial has
been registered at ClinicalTrials.gov (NCT00927615).
Study population
All consecutive STEMI patients who are candidates for pri-
mary PCI are considered eligible for participation. The
inclusion criterion is a diagnosis of STEMI as defined by
chest pain suggestive for myocardial ischemia for at least
30 minutes before hospital admission, time from onset of
symptoms of less than 12 hours, and an ECG with new ST-
segment elevation in 2 or more contiguous leads of 0.2
mV in leads V2-V3 and/or 0.1 mV in other leads or a
new-onset left bundle branch block. Exclusion criteria are
rescue PCI after thrombolytic therapy, need for emergency
coronary artery bypass grafting, presence of cardiogenic
shock, known existence of a life-threatening disease with
a life expectancy of less than 6 months, inability to pro-
vide informed consent, age below 18 years, and contra-
indications for the use of abciximab, which include active
internal bleeding, history of stroke within 2 years, recent
major surgery or intracranial or intraspinal trauma or sur-
gery within 2 months, intracranial neoplasm, arteriov-
enous malformation or aneurysm, bleeding diathesis,
severe uncontrolled hypertension, thrombocytopenia,
vasculitis, hypertensive or diabetic retinopathy, severe
liver or kidney failure, and hypersensitivity to murine pro-
teins.
Treatment
During PCI, the initial treatment step consists of manual
thrombus aspiration whenever possible. Thrombus aspi-
ration is performed with the Export aspiration catheter
(Medtronic Inc., Santa Rosa, USA) as previously described
[11]. Continuous manual suction is performed using a
proximal-to-distal approach, which is defined as active
aspiration during initial passage of the lesion. In patients
assigned to IC administration, a bolus of abciximab is
administered through the guiding catheter proximal to
the lesion in the infarct-related artery over a period of 1
minute after restoration of anterograde flow. As final step
a stent is implanted. Additional pre- or postdilatation
with a balloon may be required in certain patients.
Patients are pre-treated with aspirin (500 mg), heparin
(5000 IU IV), and high-dose clopidogrel (600 mg orally)
after electrocardiographic confirmation of STEMI, usually
in the ambulance. IC administration of nitroglycerine
(400 g) is administered during the procedure at the oper-
ator's discretion. During PCI, additional low-dose weight-
adjusted heparin is administered as guided by the acti-
vated clotting time (target: 200 - 250 seconds). Sheaths are
removed immediately at the end of the PCI procedure
using the Angio-Seal device (St. Jude Medical, Inc, St. Paul,
MN, USA) or by manual compression after arrival at the
coronary care unit. In the setting of STEMI, the femoral
Table 1: Studies comparing IC and IV administration of abciximab in patients with STEMI
Author Year* Design Patients No In favor of Main results
Wohrle et al [34] 2003 retrospective STEMI/NSTEACS 403 IC reduced incidence of MACE at 30 
days
Bellandi et al [27] 2004 prospective, randomized STEMI 45 IC higher salvage index and LV 
functional recovery 
(serial gated SPECT)
Romagnoli et al [32] 2005 prospective, matched STEMI/NSTEACS 74 IC increased coronary flow (cTFC)
Galache et al [29] 2006 prospective, randomized STEMI/NSTEACS 137 neutral no difference in the incidence of 
MACE at 1 year
Thiele et al [33] 2008 prospective, randomized STEMI 154 IC reduced infarct size and extent of 
MO (MRI at 2 days)
Dominguez-Rodriguez et al [28] 2009 prospective, randomized STEMI 50 IC larger reduction in soluble CD40 
ligand
* Year of publication
cTFC: corrected TIMI frame count; IC: intracoronary; IV: intravenous; MACE: major adverse cardiac event; MO: microvascular obstruction; MRI: 
magnetic resonance imaging; No: number of patients; NSTEACS: non-ST-elevation acute coronary syndrome; SPECT: single photon emission 
computed tomography; STEMI: ST-segment elevation myocardial infarctionTrials 2009, 10:90 http://www.trialsjournal.com/content/10/1/90
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The CICERO trial flow chart Figure 1
The CICERO trial flow chart. IC: intracoronary; IV: intravenous; PCI: percutaneous coronary intervention; STEMI: ST-seg-
ment elevation myocardial infarction.
In-hospital: enzymatic infarct size and bleeding 
complications 
30 – 60 minutes after PCI: electrocardiographic 
end points including primary end point 
Immediately after PCI: angiographic end points 
1 year: clinical outcome 
30 days: clinical outcome 
Patients with STEMI undergoing primary PCI 
N = 530 
Aspirin (500 mg) 
Heparin (5000 IU) 
Clopidogrel (600 mg) 
Coronary angiography 
Thrombus aspiration 
IC bolus of abciximab  IV bolus of abciximab 
approach is preferred. The radial approach is reserved for
patients without femoral access. In case of radial access,
sheaths are removed immediately following the PCI pro-
cedure. In patients with atrial fibrillation, a large dyski-
netic area of the left ventricle, and in immobile patients,
low-molecular-weight heparin is given for 1 to 3 days after
sheath removal. Standard therapy after PCI includes aspi-
rin (80 mg), clopidogrel (75 mg), beta-blockers, lipid
lowering agents, and angiotensin converting enzyme
inhibitors or angiotensin II receptor blockers, according
to current international guidelines [36].
Electrocardiography
A standard 12-lead electrocardiogram (ECG) is acquired
at the time of presentation and at 30 to 60 minutes after
the end of procedure. Times of onset of symptoms, admis-
sion, first intracoronary intervention, end of PCI and ECG
recordings are registered. The magnitude of ST-segment
deviation is measured 60 ms from J-point. The first post-
intervention ECG at 30 to 60 minutes is classified by com-
parison of the ST-segments with those of the ECG at pres-
entation. ST-segment elevation resolution is categorized
as complete (>70%), partial (30-70%), or absent (<30%)
[6]. On the post-interventional ECG, residual ST-segment
deviation is calculated as the sum of residual ST-segment
elevation and depression in all leads [37]. New-onset of QTrials 2009, 10:90 http://www.trialsjournal.com/content/10/1/90
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waves on the post-interventional ECG is defined as an ini-
tial negative deflection of the QRS complex of >0.1 mV
and >40 ms in an ECG lead related to the myocardial area
of infarction together with all pathological Q waves. All
ECG recordings are analyzed by a physician blinded to
treatment allocation and clinical data.
Coronary angiography
The following baseline, peri- and post-procedural angio-
graphic features are recorded: the presence of thrombus
and collaterals, Thrombolysis In Myocardial Infarction
(TIMI) flow grades, myocardial blush grade (MBG), and
the presence of angiographically visible distal emboliza-
tion. TIMI flow grades are estimated as previously
described [38]. Thrombus is assessed according to the cri-
teria summarized by Mabin et al [39]. These criteria
include the presence of an intraluminal central filling
defect or lucency surrounded by contrast material that is
seen in multiple projections, the absence of calcium
within the defect; and persistence of contrast material
within the lumen. Collaterals are assessed according to
Rentrop's classification [40]: 0 = none, 1 = filling of side
branches only, 2 = partial filling of the epicardial segment,
3 = complete filling of the epicardial segment. Evaluation
of MBG is performed as described by van 't Hof et al [7]:
0 = no myocardial blush, 1 = minimal myocardial blush
or contrast density, 2 = moderate myocardial blush or
contrast density, but less than that obtained during angi-
ography of a contra- or ipsilateral non-infarct-related cor-
onary artery, and 3 = normal myocardial blush or contrast
density, comparable with that obtained during angiogra-
phy of a contra- or ipsilateral non-infarct-related coronary
artery. Persisting myocardial blush ("staining") suggests
leakage of contrast medium into the extravascular space
and is graded 0. In addition, MBG is quantified with the
Quantitative Blush Evaluator (QuBE) as described by
Vogelzang et al [41], which provides a computer-assisted
and more operator-independent score by calculating the
increase and decrease of myocardial contrast density in
the myocardial area of interest. Distal embolization is
considered to have occurred if new circumscribed filling
defects and/or abrupt cutoff of the vessel distal to the tar-
get lesion appears [42,43]. The coronary angiograms are
analyzed by a physician who is blinded to treatment allo-
cation and clinical data.
Infarct size
Infarct size is estimated by serial measurements of cardiac
markers including creatinine kinase (CK), myocardial
band fraction of CK (CK-MB), lactate dehydrogenase
(LDH), and troponin T. Blood is sampled at baseline and
at 3, 6, 9, 12, 18, 24, and 48 hours after PCI. Peak release,
time to peak release as well as area under the curve is
determined. Marker levels are determined on a Hitachi
717 automatic analyzer according to the International
Federation of Clinical Chemistry (IFCC) recommenda-
tion.
End points assessment
The primary end point is the incidence of ST-segment res-
olution >70% as assessed on the ECG acquired 30 to 60
minutes after PCI compared to the ECG at presentation.
Secondary end points include:
- Angiographic end points: post-procedural TIMI flow,
MBG (by visual estimation and with the QuBE pro-
gram) and angiographically visible distal emboliza-
tion
- Electrocardiographic end points: residual ST-segment
deviation 30 to 60 minutes after the procedure
- Enzymatic infarct size
- Mortality and Major Adverse Cardiac Events (MACE,
a combined end point of target vessel revasculariza-
tion, reinfarction, and cardiovascular mortality) at 30
days and 1 year.
A safety endpoint consists of in-hospital bleeding compli-
cations.
Furthermore, the primary and secondary endpoints are to
be analyzed in pre-specified subgroups, which are defined
as:
1. Age (<65 versus >65 years)
2. Gender
3. Presence of diabetes
4. Number of diseased vessels (multi-vessel versus sin-
gle vessel)
5. Infarct-related artery (left anterior descending artery
(LAD) versus non-LAD)
6. Ischemic time (<3 versus >3 hours)
7. Angiographic presence of thrombus
8. Pre-procedural TIMI flow
9. Post-procedural TIMI flow
10. Post-procedural myocardial blush gradeTrials 2009, 10:90 http://www.trialsjournal.com/content/10/1/90
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Clinical follow-up
Death, reinfarction, and ischemia driven target-vessel
revascularization are to be registered at 30 days and 1 year.
Follow-up information will be obtained from the central
personal records database, hospital records as well as by
telephone interviews with the patients and/or their gen-
eral practitioners.
Statistical considerations
Sample size estimation
In previously published data, the incidence of our primary
end point resolution of ST-segment elevation >70% has
been reported to be 56.6% in patients with STEMI treated
with thrombus aspiration [11]. We hypothesize that IC
administration of abciximab during PCI increases the
incidence of ST-segment resolution >70% by 25%. To
detect a 25% difference between the two treatment
groups, 530 patients are required to reach a 5% signifi-
cance level (two-sided) with 90% power.
Statistical analysis
All statistical analyses will be performed according to the
intention-to-treat principle for the overall population as
well as for the pre-specified subgroups. Statistical signifi-
cance is considered as a two-tailed p value less than 0.05.
The Statistical Package for the Social Sciences (SPSS Inc.,
Chicago, IL, USA) version 16.0.2 will be used for all statis-
tical analyses. Differences between group means will be
assessed with the two-tailed Student's t-test. Chi-square
analysis or Fisher's exact test will be used to test differ-
ences between proportions. Survival will be calculated by
the Kaplan-Meier product-limit method. Chi-square anal-
ysis will be used to assess the relation between an individ-
ual variable and end points. The Mantel-Cox (or log-rank)
test will be used to evaluate differences in survival
between the two treatment groups. The Cox proportional-
hazards regression model will be used to calculate relative
risks and to adjust for differences in baseline characteris-
tics.
Discussion
The CICERO trial is a single-center, prospective, rand-
omized trial to determine whether IC administration of
abciximab during primary PCI is more effective than IV
administration in improving myocardial perfusion in
STEMI patients undergoing primary PCI with thrombus
aspiration. This is the first large clinical trial to date to
determine the effect of IC versus IV administration of
abciximab in STEMI patients undergoing primary PCI
with thrombus aspiration.
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